Only half of US veterans who died from cancer received palliative care, while the use of hospice depended upon the care environment. Overall, there was a gap between the percentage of patients who received palliative care and recommended use.
Only half of US veterans who died from cancer received palliative care, while the use of hospice depended upon the care environment, according to a study published in the Journal of Palliative Medicine.
Risha Gidwani, DrPH, health economist at the Veterans Affairs Palo Alto Health Economics Resource Center and consulting assistant professor of medicine at Stanford University School of Medicine, and colleagues studied the care of 11,896 veterans over the age of 65 with cancer who died in 2012, and found that 71% of them received hospice care but only 52% received palliative care. They note that medical societies, including the American Society of Clinical Oncology, recommend that patients with advanced cancer get palliative care soon after diagnosis and hospice care for at least the last 3 days of their life.
Palliative care is meant to alleviate symptoms and improve quality of life, and is appropriate for all patients with serious illness, not only those at the end of life. Hospice care, however, is end-of-life care, which can provide social support for family members, and can be recommended by practitioners only if they believe the patient has fewer than 180 days to live.
The researchers also found that exposure to hospice care differed significantly between patients treated by the Department of Veterans Affairs (VA) and those enrolled in Medicare. Many patients who received palliative care did so late in their disease progression rather than immediately after diagnosis, as recommended. The study found the patients getting VA care were less likely to get hospice care for the minimum recommended 3 days, compared with those in Medicare or other contracted care paid for by the VA. VA patients first received hospice care a median of 14 days before they died, compared with patients in VA-contracted care, who got hospice a median of 28 days before death. The timing of care should not be any different, the authors noted, and patients should get a service based on clinical need, not the health system they’re in.
Medicare and the VA were found to have different policies on using hospice care. VA cancer patients can continue getting curative treatment while in hospice, whereas Medicare patients must stop any chemotherapy or radiation before beginning hospice. There were also differences in the use of hospice and palliative care between cancer types and ages.
“Our work indicates palliative care needs to be better integrated into standard oncological care and that there is wide variation in receipt of hospice care,” the researchers concluded.
The most important takeaway from the study is that we need to improve exposure to palliative care in terms of how many patients receive it and when they receive it, according to Gidwani.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Technology Takes Center Stage at the 2025 AAD Annual Meeting
March 14th 2025The role of artificial intelligence, DataDerm, and telehealth in advancing dermatology care was discussed throughout the meeting, with experts highlighting their potential regarding patient access and health equity.
Read More